Can Wegovy help with weight loss, and who is medically eligible in Europe?

Wegovy for weight loss explained: semaglutide 2.4 mg, GLP-1 receptor agonist therapy, BMI criteria, appetite regulation, and prescribing standards.

In this episode, we outline how Wegovy works and how doctors assess eligibility under EU medical guidance.

You’ll learn:

• What semaglutide is and how GLP-1 reduces appetite and calorie intake

• Approved BMI thresholds (≥30, or ≥27 with weight-related conditions such as hypertension or type 2 diabetes)

• Expected average weight reduction in clinical trials

• The importance of concurrent lifestyle intervention

• Common side effects: nausea, vomiting, diarrhoea, constipation

• Monitoring requirements: HbA1c, kidney function, blood pressure

• Red flag symptoms such as severe abdominal pain or persistent vomiting

• Situations where treatment requests may be declined pending full metabolic assessment

We explain how doctors assess BMI, waist circumference, cardiovascular risk, glucose markers, previous weight management attempts, medication history, and contraindications during an online consultation in the EU. Wegovy is prescribed based on approved obesity criteria and ongoing safety monitoring.

This episode reflects the clinical standards used by Mobi Doctor, where weight management consultations are reviewed by a registered physician in line with EU prescribing guidance.

Learn more here:

https://www.mobidoctor.eu/wegovy-for-weight-loss